基本信息
浏览量:119
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
个人简介
Professor Prow has a drug delivery leadership profile that is supported (since 2016) by research income >$14.5M, 35 peer-reviewed translational research publications (>140 total), six patent families and named on 19 Human Ethics Committee approvals. Professor Prow’s clinical research focus is reflected in all 23 grants and 28/35 publications, since 2016. Professor Prow’s leadership in drug delivery is evidenced by $7.5M in translational research funding (lead investigator in 11/18 projects).
Drug Delivery. A total of $1.86M of that funding was for translational, topical drug delivery projects that underpinned his drug delivery research focus on skin cancer. He led all drug delivery (7/9) grants (including Professor Prow’s NHMRC Fellowship), except two that were NHMRC fellowships for his post-doctoral fellows. These high profile NHMRC fellowships are evidence of Professor Prow’s commitment to mentorship. Professor Prow is an invited member of the Advanced Drug Delivery Reviews (5-year impact factor 15.5) editorial board, supporting his role as a global thought leader in drug delivery.
Skin Cancer. Professor Prow has built a strong international profile in the skin cancer field as evidenced by 13/19 human ethics committee approved protocols involving skin cancer and precursors, 16/35 peer-reviewed publications since 2015 with a skin cancer focus and >$10M in competitive funding skin cancer research.
Commercialisation. Translation through commercialisation is Professor Prow’s vision for his research projects. Professor Prow’s key collaboration with Almirall on topical drug-induced apoptosis in skin cancer is an important step towards that outcome. Professor Prow has a successful commercialisation track record, e.g. skin microbiopsy intellectual property, 2018 USPTO granted, is being commercialised by Trajan Sci & Med, Melbourne, AUS. Professor Prow is a named inventor of topical drug delivery technology currently licensed to Vaxxas, a $55 M start-up company.
研究兴趣
论文共 216 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Akbor Hossain,Lisa N Tom, Ala Melati-Rad,Miko Yamada, Sabrina Hammerlindl,Kasturee Jagirdar,Tarl W Prow,H Peter Soyer,Mitchell S Stark
Skin health and diseaseno. 3 (2024): e360-e360
JOURNAL OF MOLECULAR DIAGNOSTICSno. 1 (2023): 17-35
JMIR dermatologyno. 2 (2022): e37034-e37034
Journal of the American Academy of Dermatologyno. 4 (2022): 903-904
Environmental Researchno. Pt C (2022): 113431-113431
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn